Articles By Cathy Yarbrough`

  1. 5-Year Survey Reveals Supply Chain Product Protection Concern 11/29/2012

    The security and integrity of drugs and medical devices are a growing concern to supply chain and logistic executives especially in emerging markets.

  2. Biopharms Embrace Companion Diagnostics To Advance Personalized Medicine & Address Drug Costs Concerns 10/31/2012

    Even though oncology dominates the CDx market, biopharmaceutical companies have not ignored other disease area. CDx provides a way for biopharma companies to address payers’ concerns about costs of medical treatment due to its potential to limit new drugs to only those patients who stand to benefit.

  3. Three Words That Can Determine Patent Ownership 6/28/2012

    Three words that could determine ownership of an invention, “and hereby assigns”, are often missing from employment agreements in the life sciences industry.

  4. A Biotech's Path To Acquisition 3/8/2012

    During the final days of 2011, Steve Worland, Ph.D., and his 26 colleagues at Anadys Pharmaceuticals transferred their work — and the company’s assets in hepatitis C (HCV) drug development — to Roche Holding AG. Dr. Worland, CEO and president of the company since 2007, and his staff no doubt also spent some time updating their CVs, because in late November, the Swiss pharmaceutical company finalized its takeover of the San Diego company.

  5. Protecting Pharma Manufacturing Workers With Barrier/Containment Technologies 2/9/2012

    Because of recent advances in genomics and other fields of science, biopharmaceutical companies and CMOs are producing medications that are much more potent than their predecessors. As a result, both industry and the federal Occupational Safety and Health Agency (OSHA) are focusing more on the safety of workers in pharmaceutical manufacturing.

  6. Tips For Entrepreneurs Seeking Angel Investment 8/12/2011

    For a first-time entrepreneur who is seeking angel funding to launch a life sciences company, the “exit strategy” may not be top-of-mind. It is for angel investors, those high net-worth investors who individually or as a member of an organized group provide seed and start-up financing in exchange for an ownership stake in the company, usually in preferred stock or convertible debt.

  7. Paperless, Integrated, Clinical Trial Management: Almost There 5/19/2011

    Imagine a clinical trial without large study binders crammed with paper copies of the protocol, the investigator’s brochure, patient consent forms, and the other documents necessary to perform a multicenter study from start-up to closeout.